Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Other hematologic neoplasm 4Other solid neoplasm 3Gastrointestinal 3Myeloid 2Dermatologic 2Tumor-Agnostic 1Other neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Prostate Cancer Patients Undergoing Radical Prostatectomy 1

Interventions

Docetaxel 409pembrolizumab 331Prednisone 289enzalutamide 283Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 252Abiraterone Acetate 217Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 117Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 106cabozantinib 104atezolizumab 104Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Infusions, Intravenous × Genitourinary × Clear all
NCT07024030 2025-06-17

DGPR1008

The Affiliated Hospital of Qingdao University

Phase 2 Completed
24 enrolled
Genitourinary

Prostate Cancer Patients Undergoing Radical Prostatectomy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡